ANI Pharmaceuticals made a recommended public offer to acquire Egetis Therapeutics, valuing the deal at about $560 million including incentive programs and reflecting the separate sale of Egetis’s priority review voucher for $190 million. Egetis’s Emcitate has approvals in the EU and FDA for peripheral thyrotoxicosis in MCT8 deficiency, providing ANI a rare-disease revenue base alongside the voucher-driven transaction structure.